替格瑞洛停药三天与围术期出血并发症的关联
该回顾性队列分析纳入2013年1月至2017年9月接受冠状动脉旁路移植或单瓣膜手术的3377例患者,比较术前暴露于替格瑞洛者与仅暴露于阿司匹林者的围术期出血结局。倾向性评分匹配后显示,替格瑞洛暴露与主要出血并发症风险升高相关(31% vs 12%,RR 2.6,95%CI 1.4-4.8),且0-72小时内暴露风险更高(48% vs 10%,RR 5.0,95%CI 1.9-13.4),而72-120小时暴露无显著关联(17% vs 15%,RR 1.1,95%CI 0.4-2.9)。
要点
- 替格瑞洛术前暴露与主要出血并发症风险升高相关。
- 0-72小时内暴露风险显著增加,72-120小时暴露无显著关联。
- 研究提示3天停药可能不足以完全避免主要出血风险。
核心结论
- 替格瑞洛术前0-72小时暴露与心脏手术后主要出血并发症风险升高相关。
- 替格瑞洛术前72-120小时暴露与主要出血并发症的临床相关增加无显著关联。
研究设计与样本
- 回顾性队列分析,纳入2013年1月至2017年9月接受冠状动脉旁路移植或单瓣膜手术的3377例患者。
- 替格瑞洛暴露组101例,阿司匹林对照组3276例,倾向性评分匹配后形成90对患者。
主要发现
- 替格瑞洛暴露组主要出血并发症发生率为31%,对照组为12%,相对风险2.6(95%CI 1.4-4.8)。
- 术前0-72小时替格瑞洛暴露(n=42)主要出血并发症发生率为48%,对照组为10%,相对风险5.0(95%CI 1.9-13.4)。
- 术前72-120小时替格瑞洛暴露(n=48)主要出血并发症发生率为17%,对照组为15%,相对风险1.1(95%CI 0.4-2.9)。
临床怎么用
- 对于择期心脏手术患者,需关注替格瑞洛末次给药时间与手术间隔。
- 术前0-72小时内暴露于替格瑞洛的患者可能需加强围术期出血监测与准备。
局限性
- 本研究为回顾性历史队列分析,可能存在残余混杂。
- 替格瑞洛暴露组样本量较小,匹配后仅90对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Dual antiplatelet therapy at the time of cardiac surgery is associated with excessive perioperative bleeding. International guidelines, therefore, recommended discontinuing oral adenosine diphosphate receptor antagonists prior to non-emergency surgery. In this study, we analysed whether a 3-day ticagrelor discontinuation was sufficient to avoid major bleeding complications. METHODS: This study is a retrospective cohort analysis of 3377 patients undergoing coronary artery bypass or single-valve surgery from January 2013 to September 2017. Patients exposed to ticagrelor prior to surgery were compared with control patients exposed to aspirin only. Outcome measures included transfusion requirements, bleeding volumes, the need for re-exploration and the composite outcome major bleeding complication. Data were retrieved from the the Western Denmark Heart Registry. RESULTS: During the study period, 101 patients were preoperatively exposed to ticagrelor, whereas 3276 patients were exposed to aspirin only. Propensity-score matching resulted in 90 pairs of patients. Overall, ticagrelor exposure was associated with a greater risk of major bleeding complications compared with control patients [31 vs 12%, relative risk 2.6, 95% confidence interval (CI) 1.4-4.8]. While ticagrelor exposure within 0-72 h before surgery (n = 42) was associated with a substantially increased risk of major bleeding complications (48 vs 10%, relative risk 5.0, 95% CI 1.9-13.4), ticagrelor exposure 72-120 h before surgery (n = 48) showed no statistically significant association (17 vs 15%, relative risk 1.1, 95% CI 0.4-2.9). CONCLUSIONS: In our historical cohort, ticagrelor exposure 0-72 h prior to cardiac surgery was associated with an increased risk of major bleeding complications. On the other hand, ticagrelor exposure 72-120 h prior to surgery was not associated with a clinically relevant increase in major bleeding complications.
引用
- Kremke M, Gissel MS, Jensen MJ, et al. The association between a three-day ticagrelor discontinuation and perioperative bleeding complications. Eur J Cardiothorac Surg. 2019. PMID: 30358828. doi:10.1093/ejcts/ezy355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。